Table 1.

Inclusion and exclusion criteria for MS patients.

Inclusion criteria 1. Diagnosis of RRMS, SPMS, or PPMS according to the 2017 revised McDonald criteria 2. Informed consent to participate in the study 3. Age 18 to 75 years old at time of inclusion 4. At least two documented SARS-CoV-2 vaccinations

Exclusion criteria 1. Patients who switched DMTs since the first vaccine dose 2. Medical, psychiatric, cognitive, or other conditions that compromise the patient’s ability to understand the patient information and to give informed consent 3. Treatment with mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, or methotrexate within the last 5 years 4. Any previous treatment with alemtuzumab, cyclophosphamide, total body irradiation, or bone marrow transplantation 5. Patients who received immunosuppressants for diseases other than MS or who received long-term corticosteroid treatment 6. Patients with verified infection by human immunodeficiency virus or hepatitis C virus 7. Patients with a systemic autoimmune disorder 8. Patients with medical history of COVID-19 infection or positive abs to the SARS-CoV-2 spike protein and/or nucleocapsid protein before the first vaccine dose Regarding patients who received anti-SARS-CoV-2-ab testing and measurement of the SARS-CoV-2-specific T cell response 1. Previous treatment with other B cell modulating therapies (e.g., rituximab, atacicept, belimumab, or ofatumumab) before the start of OCR

ab, antibody, COVID-19, Coronavirus disease 2019, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.